As of now, there are no GLP-1 agonists approved for treatment of Parkinsons disease
Additionally, GLP-1RAs exert cardiovascular benefits, including improved endothelial function, reduced blood pressure, and cardioprotection
[5] On May 5, 2010 the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco) became the first governmental health organization ever (even before the drug received approval in Europe) to authorize afamelanotide as a medicine for therapeutic treatment of Italian citizens to reduce painful photosensitivity stemming from the orphan disease erythropoietic protoporphyria (EPP)
But specifically for this population, we know that cancer survivors are at greater than a doubling in risk of cardiometabolic disorders and cardiometabolic mortality, and some emerging data that perhaps weight loss may help to lower recurrence risk after a cancer diagnosis
But the war disrupted his work which he only resumed in 1920
Then, in February 2025, FDA removed semaglutide from its shortage list, giving some pharmacies, called 503A pharmacies, until April 22, 2025, to stop dispensing exact copies of semaglutide, and others, so-called 503B pharmacies, until May 22, 2025